# US 2024/0199571 A1 · Thiophene compound and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199571 A1
- Document ID: US20240199571A1
- Status: Published application
- Kind: A1
- Application number: 18/549,188
- Filed: 2022-03-04
- Published: 2024-06-20
- Earliest claimed: 2021-03-11
- Assignees: Medshine Discovery Inc.
- Applicants: Medshine Discovery Inc.
- Inventors: Lingyun WU; Zhen ZHAN; Lele ZHAO; Jianjun SUN; Yi QIAN; Shuhui CHEN
- Web page: https://patentgrep.com/patent/US20240199571A1

## CPC

- C07D 333/22: Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
- C07D 409/14: containing three or more hetero rings
- A61K 31/381: having five-membered rings
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 35/00: Antineoplastic agents
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/10: linked by a carbon chain containing aromatic rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a thiophene compound and an application thereof. The present invention specifically relates to a compound represented by formula (II) and a pharmaceutically acceptable salt thereof, wherein L1 is —C(═O)— or —C(═O)—NH—; R1 is R1a or aa; ring A is bb or cc; R1a is C1-3 alkyl substituted with 1, 2 or 3 Ra; and R3 is independently H, halogen or C1-3 alkoxy. The compound represented by formula (II) and the pharmaceutically acceptable salt thereof can better inhibit the activity of LSD1, further shows significant inhibitory activity against NCI-H1417 cell proliferation, and has good pharmacokinetic properties (including good oral bioavailability, oral exposure, half-life, and clearance rate, etc.).

## Claims

### Claim 1

A compound of formula (II) or a pharmaceutically acceptable salt thereof,
wherein L1 is —C(═O)— or —C(═O)—NH—;
R1 is R1a or
ring A is
T1 is CH or N;
T2 is CR2c or N;
T3 is CR2 or N;
T4 is CR2b or N;
E1 is a single bond, —C(R5)2—, or —C(R5)2C(R5)2—;
E2 is —NR6— or —C(R61)2—;
E3 is a single bond, —C(R7)2—, or —C(R7)2C(R7)2—;
E4 is O, S, CH2, or NR2g;
E5 is O, CH2, or NR2g;
R1a is C1-3 alkyl substituted by 1, 2, or 3 Ra;
R2a is H or halogen;
R2 and R2b are each independently H, halogen, NH2, C1-3 alkyl, C1-3 alkoxy, —S(═O)2C1-3 alkyl, —NHC1-3 alkyl, 4- to 6-membered heterocycloalkyl, —C(═O)-4- to 6-membered heterocycloalkyl, or —NHC1-3 alkyl-C3-6 cycloalkyl, wherein the C1-3 alkyl, C1-3 alkoxy, —S(═O)2C1-3 alkyl, —NHC1-3 alkyl, 4- to 6-membered heterocycloalkyl, —C(═O)-4- to 6-membered heterocycloalkyl, and —NHC1-3 alkyl-C3-6 cycloalkyl are each independently and optionally substituted by 1, 2, or 3 Rb;
R2c is H;
or, R2 and R2c, together with the C atom to which they are attached, make the structural moiety
T5, T6, T7, T8, T9, T10, and T11 are each independently N or CRt;
W1 is O or NR2d;
R2d is H, C1-4 alkyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, —C1-3 alkyl-C3-6 cycloalkyl, or —C1-3 alkyl-4- to 6-membered heterocycloalkyl, wherein the C1-4 alkyl, C3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, —C1-3 alkyl-C3-6 cycloalkyl, and —C1-3 alkyl-4- to 6-membered heterocycloalkyl are each independently and optionally substituted by 1, 2, or 3 Rc;
R2e, R2f, and R2g are each independently H or C1-3 alkyl;
each R3 is independently H, halogen, or C1-3 alkoxy;
R4 and R8 are each independently H or C1-3 alkyl;
each R5 is independently H, halogen, OH, NH2, C1-3 alkyl, —NHC1-3 alkyl, or —N(C1-3 alkyl)2, wherein the C1-3 alkyl, —NHC1-3 alkyl, and —N(C1-3 alkyl)2 are each independently and optionally substituted by 1, 2, or 3 Rd;
R6 is H or C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted by 1, 2, or 3 Re;
each R61 is independently H, halogen, OH, NH2, or C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted by 1, 2, or 3 Rf;
each R7 is independently H, halogen, OH, NH2, C1-3 alkyl, —NHC1-3 alkyl, or —N(C1-3 alkyl)2, wherein the C1-3 alkyl, —NHC1-3 alkyl, and —N(C1-3 alkyl)2 are each independently and optionally substituted by 1, 2, or 3 Rg;
or, when E1 is —C(R5)2—, E2 is —C(R61)2—, and E3 is a single bond, R5 and R61, together with the C atom to which they are attached, make the structural moiety
or, when E2 is —C(R61)2—, two R61, together with the C atom to which they are attached, make the structural moiety
or, when E3 is a single bond, R4 and R8, together with the C atom to which they are attached, make the structural moiety
or, when T1 is CH and E1 is —C(R5)2—, R5 and R8, together with the C atom to which they are attached, make the structural moiety
E6 is NR6c or O;
R6a and R6b are each independently H, halogen, OH, ═O, NH2, or C1-3 alkyl;
R6c is H or C1-3 alkyl;
Ra, Rb, Rc, Rd, Re, Rf, and Rg are each independently F, Cl, Br, OH, CN, COOH, NH2, C1-3 alkyl, or C1-3 alkoxy;
each Rt is independently H, F, Cl, Br, OH, CN, COOH, NH2, C1-3 alkyl or C1-3 alkoxy;
n is 1 or 2;
the 4- to 6-membered heterocycloalkyl contains 1, 2, 3, or 4 heteroatoms or heteroatom groups independently selected from —O—, —NH—, —S—, and N.

### Claim 2 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is
wherein
R2 is H, halogen, NH2, C1-3 alkyl, C1-3 alkoxy, —S(═O)2C1-3 alkyl, —NHC1-3 alkyl, 4- to 6-membered heterocycloalkyl, —C(═O)-4- to 6-membered heterocycloalkyl, or —NHC1-3 alkyl-C3-6 cycloalkyl, wherein the C1-3 alkyl, C1-3 alkoxy, —S(═O)2C1-3 alkyl, —NHC1-3 alkyl, 4- to 6-membered heterocycloalkyl, —C(═O)-4- to 6-membered heterocycloalkyl, and —NHC1-3 alkyl-C3-6 cycloalkyl are each independently and optionally substituted by 1, 2, or 3 Rb.

### Claim 3 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein Ra, Rb, Rc, Rd, Re, Rf, and Rg are each independently F, Cl, Br, OH, CN, COOH, NH2, CH3, or OCH3.

### Claim 4 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein each Rt is independently H, F, Cl, or CH3;
or, R2a is H or F;
or, R2d is H, CH3,
wherein the CH3,
are optionally substituted by 1, 2, or 3 Rc;
or, R6a and R6b are each independently H, OH, ═O, NH2, or CH3;
or, R6c is H or CH3.

### Claim 5 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R1a is
substituted by 1, 2, or 3 Ra;
or, R2 and R2b are each independently H, F, Cl, NH2, —OCH3,
wherein the —OCH3,
are each independently and optionally substituted by 1, 2, or 3 Rb,
or, R2e, R2f, and R2g are each independently H or CH3;
or, each R3 is independently F or OCH3:
or, each R5 is independently H, F, Cl, Br, I, OH, NH2, CH3, —NH—CH3, or
wherein the CH3, —NH—CH3, and
are each independently and optionally substituted by 1, 2, or 3 Rd;
or, R6 is H, CH3, or CH2—CH3, wherein the CH3 and CH2—CH3 are each independently and optionally substituted by 1, 2, or 3 Re;
or, each R61 is independently H, F, Cl, Br, I, OH, NH2, or CH3, and the CH3 is optionally substituted by 1, 2, or 3 Rf;
or, each R7 is independently H, F, Cl, Br, I, OH, NH2, CH3, —NH—CH3, or
and the CH3, —NH—CH3, and
are optionally substituted by 1, 2, or 3 Rg;
or, the salt is hydrochloride.

### Claim 6 (depends on 5)

The compound or the pharmaceutically acceptable salt thereof according to claim 5, wherein R1a is
or, R2 and R2b are each independently H, F, Cl, NH2, —OCH3,
or, each R5 is independently H, OH, NH2, CH3, or
or, R6 is H, CH2—CN, or CH2—CF3;
or, each R61 is independently H, F, OH, or NH2;
or, each R7 is independently H, OH, NH2, CH3, or

### Claim at position 7

7-10. (canceled)

### Claim 11 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R2d is H, CH3,

### Claim at position 9

12-13. (canceled)

### Claim 14 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R4 and R8 are each independently H or CH3.

### Claim at position 11

15-25. (canceled)

### Claim 26 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the structural moiety

### Claim 27 (depends on 26)

The compound or the pharmaceutically acceptable salt thereof according to claim 26, wherein the structural moiety

### Claim at position 14

28-29. (canceled)

### Claim 30 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the structural moiety

### Claim 31 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the structural moiety

### Claim 32 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R1 is
or, ring A is

### Claim 33

(canceled)

### Claim 34 (depends on 32)

The compound or the pharmaceutically acceptable salt thereof according to claim 32, wherein ring A is

### Claim 35 (depends on 1)

The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is
wherein
R2 and R2b are each independently H, halogen, NH2, C1-3 alkyl, C1-3 alkoxy, —S(═O)2C1-3 alkyl, 4- to 6-membered heterocycloalkyl, or —C(═O)-4- to 6-membered heterocycloalkyl, wherein the C1-3 alkyl, C1-3 alkoxy, —S(═O)2C1-3 alkyl, 4- to 6-membered heterocycloalkyl, and —C(═O)-4- to 6-membered heterocycloalkyl are each independently and optionally substituted by 1, 2, or 3 Rb.

### Claim 36 (depends on 35)

The compound or the pharmaceutically acceptable salt thereof according to claim 35, wherein the compound is

### Claim 37 (depends on 36)

The compound or the pharmaceutically acceptable salt thereof according to claim 36, wherein the compound is

### Claim 38

A compound of the following formula or a pharmaceutically acceptable salt thereof, selected from,

### Claim 39 (depends on 38)

The compound or the pharmaceutically acceptable salt thereof according to claim 38, selected from,

### Claim 40

(canceled)

### Claim 41 (depends on 1)

A method for treating diseases related to LSD1 in a subject in need thereof, comprising administering the compound or the pharmaceutically acceptable salt thereof according to claim 1 to the subject.
